Physician profile
Catherine Ensinger
NPI 1053076448
$10,820.02
in general payments reported to CMS, 2019-2025
24 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $3,623 · 2023: $2,958 · 2024: $2,313 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,836.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,869.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,741.09 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Corcept Therapeutics | $1,378.49 | 2021-2025 | Korlym |
| Mannkind Corporation | $1,197.34 | 2021-2025 | Afrezza |
| Lilly USA, LLC | $1,061.97 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $515.84 | 2022-2024 | |
| Cequr Corporation | $500.43 | 2023-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.69 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Medtronic, INC. | $398.03 | 2022-2025 | Minimed 780g, Minimed 770g |
| Insulet Corporation | $305.61 | 2022-2025 | Omnipod |
| Abbvie INC. | $279.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $188.28 | 2022-2023 | |
| Dexcom, INC. | $178.61 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $171.62 | 2022-2023 | Steglatro, Steglujan, Verquvo |
| Xeris Pharmaceuticals, INC. | $146.86 | 2023-2024 | Recorlev, Gvoke Hypopen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $110.67 | 2023 | Jornay Pm |
| Eusa Pharma (US) LLC | $73.54 | 2022 | |
| Recordati_rare_diseases_inc. | $73.54 | 2022 | |
| Abbott Laboratories | $49.28 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Averitas Pharma INC. | $34.91 | 2023-2024 | Qutenza |
| Tandem Diabetes Care, INC. | $23.96 | 2022 | |
| Sequel Med Tech, LLC | $23.13 | 2025 | Twiist |
| Kowa Pharmaceuticals America, INC. | $17.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Ensinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.